Salute e Benessere
Sapphiros announces a strategic agreement with Roche, providing Roche access to 1 billion lateral flow tests and access to future molecular point-of-care tests
Under this partnership, Roche will also gain access to Sapphiros' future novel molecular multiplex technology. The single user step, instrument-free, connected, multiplex molecular platform will deliver affordable lab quality performance to point-of-care and home self-testing.
Sapphiros is committed to making diagnostics simple, scalable and accessible. This partnership advances that mission and supports governments, health systems and communities in mitigating future pandemics through rapid and reliable testing.
About Sapphiros
Sapphiros, backed by KKR and Neoenta, is a privately held consumer diagnostics company. Sapphiros' portfolio of technologies and capabilities includes novel sample collection, next generation diagnostics, and extreme volume manufacturing, which help consumers and communities access important diagnostic results.
For more information visit www.sapphiros.com
For Media Relations email press@sapphiros.com
Logo - https://mma.prnewswire.com/media/1895080/Sapphiros_2025_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sapphiros-announces-a-strategic-agreement-with-roche-providing-roche-access-to-1-billion-lateral-flow-tests-and-access-to-future-molecular-point-of-care-tests-302619517.html